During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

Athira Pharma has been on a bumpy road in recent years, and now the company is restructuring and shedding weight to try to ...

The first phase of what eventually will be the country’s largest truck stop is set to open Oct. 1 off Interstate 90 in West ...

Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results ...

The next morning, Sept. 16, Hawaiian Volcano Observatory scientists on a helicopter overflight confirmed that a small ...

Plus: LiquidStack raises $20 Million in Series B extension investment, HEST Investments secures $1.8 million SPV investment ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...